Oliver Strobel1, Nigora Dadabaeva2, Klaus Felix2, Thilo Hackert2, Nathalia A Giese2, Ralf Jesenofsky3, Jens Werner2. 1. Department of General Surgery, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany. oliver.strobel@med.uni-heidelberg.de. 2. Department of General Surgery, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany. 3. Department of Internal Medicine 2, University Medicine Mannheim, Mannheim, Germany.
Abstract
BACKGROUND: Pancreatic stellate cells (PSCs) play a critical role in pancreatic ductal adenocarcinoma (PDAC). Activated PSCs are the main source of fibrosis in chronic pancreatitis and of desmoplasia in PDAC. The majority of studies on PSC are based on in vitro experiments relying on immortalized cell lines derived from diseased human pancreas or from animal models. These PSCs are usually activated and may not represent the biological context of their tissue of origin. PURPOSE: (1) To isolate and culture primary human PSC from different disease contexts with minimal impact on their state of activation. (2) To perform a comparative analysis of phenotypes of PSC derived from different contexts. METHODS: PSCs were isolated from normal pancreas, chronic pancreatitis, and PDAC using a hybrid method of digestion and outgrowth. To minimize activation by serum compounds, cells were cultured in a low-serum environment (2.5 % fetal bovine serum (FBS)). Expression patterns of commonly used markers for PSC phenotype and activity were compared between primary PSC lines derived from different contexts and correlated to expression in their original tissues. RESULTS: Isolation was successful from 14 of 17 tissues (82 %). Isolated PSC displayed stable viability and phenotype in low-serum environment. Expression profiles of isolated PSC and matched original tissues were closely correlated. PDAC-derived PSC tended to have a higher status of activation if compared to PSC derived from non-cancerous tissues. CONCLUSIONS: Primary human PSCs isolated from different contexts and cultured in a low-serum environment maintain a phenotype that reflects the stromal activity present in their tissue of origin.
BACKGROUND:Pancreatic stellate cells (PSCs) play a critical role in pancreatic ductal adenocarcinoma (PDAC). Activated PSCs are the main source of fibrosis in chronic pancreatitis and of desmoplasia in PDAC. The majority of studies on PSC are based on in vitro experiments relying on immortalized cell lines derived from diseased humanpancreas or from animal models. These PSCs are usually activated and may not represent the biological context of their tissue of origin. PURPOSE: (1) To isolate and culture primary human PSC from different disease contexts with minimal impact on their state of activation. (2) To perform a comparative analysis of phenotypes of PSC derived from different contexts. METHODS: PSCs were isolated from normal pancreas, chronic pancreatitis, and PDAC using a hybrid method of digestion and outgrowth. To minimize activation by serum compounds, cells were cultured in a low-serum environment (2.5 % fetal bovine serum (FBS)). Expression patterns of commonly used markers for PSC phenotype and activity were compared between primary PSC lines derived from different contexts and correlated to expression in their original tissues. RESULTS: Isolation was successful from 14 of 17 tissues (82 %). Isolated PSC displayed stable viability and phenotype in low-serum environment. Expression profiles of isolated PSC and matched original tissues were closely correlated. PDAC-derived PSC tended to have a higher status of activation if compared to PSC derived from non-cancerous tissues. CONCLUSIONS: Primary human PSCs isolated from different contexts and cultured in a low-serum environment maintain a phenotype that reflects the stromal activity present in their tissue of origin.
Authors: Thiruvengadam Arumugam; Will Brandt; Vijaya Ramachandran; Tood T Moore; Huamin Wang; Felicity E May; Bruce R Westley; Rosa F Hwang; Craig D Logsdon Journal: Pancreas Date: 2011-08 Impact factor: 3.327
Authors: Max G Bachem; Marion Schünemann; Marco Ramadani; Marco Siech; Hans Beger; Andreas Buck; Shaoxia Zhou; Alexandra Schmid-Kotsas; Guido Adler Journal: Gastroenterology Date: 2005-04 Impact factor: 22.682
Authors: Alain Vonlaufen; Swapna Joshi; Changfa Qu; Phoebe A Phillips; Zhihong Xu; Nicole R Parker; Cheryl S Toi; Romano C Pirola; Jeremy S Wilson; David Goldstein; Minoti V Apte Journal: Cancer Res Date: 2008-04-01 Impact factor: 12.701
Authors: Jennifer M Bailey; Benjamin J Swanson; Tomofumi Hamada; John P Eggers; Pankaj K Singh; Thomas Caffery; Michel M Ouellette; Michael A Hollingsworth Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: M V Apte; P S Haber; T L Applegate; I D Norton; G W McCaughan; M A Korsten; R C Pirola; J S Wilson Journal: Gut Date: 1998-07 Impact factor: 23.059
Authors: M G Bachem; E Schneider; H Gross; H Weidenbach; R M Schmid; A Menke; M Siech; H Beger; A Grünert; G Adler Journal: Gastroenterology Date: 1998-08 Impact factor: 22.682
Authors: Mara H Sherman; Ruth T Yu; Dannielle D Engle; Ning Ding; Annette R Atkins; Herve Tiriac; Eric A Collisson; Frances Connor; Terry Van Dyke; Serguei Kozlov; Philip Martin; Tiffany W Tseng; David W Dawson; Timothy R Donahue; Atsushi Masamune; Tooru Shimosegawa; Minoti V Apte; Jeremy S Wilson; Beverly Ng; Sue Lynn Lau; Jenny E Gunton; Geoffrey M Wahl; Tony Hunter; Jeffrey A Drebin; Peter J O'Dwyer; Christopher Liddle; David A Tuveson; Michael Downes; Ronald M Evans Journal: Cell Date: 2014-09-25 Impact factor: 41.582
Authors: Matias Estaras; Noelia Moreno; Patricia Santofimia-Castaño; Salome Martinez-Morcillo; Vicente Roncero; Gerardo Blanco; Diego Lopez; Miguel Fernandez-Bermejo; Jose M Mateos; Juan L Iovanna; Gines M Salido; Antonio Gonzalez Journal: J Physiol Biochem Date: 2019-03-13 Impact factor: 4.158
Authors: Verena M Throm; David Männle; Thomas Giese; Andrea S Bauer; Matthias M Gaida; Juergen Kopitz; Thomas Bruckner; Konstanze Plaschke; Svetlana P Grekova; Klaus Felix; Thilo Hackert; Nathalia A Giese; Oliver Strobel Journal: Oncotarget Date: 2018-01-24